Unilateral primary osteoarthritis, unspecified knee
Methodology & AI Transparency ⓘ
Unilateral primary osteoarthritis, unspecified knee Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Unilateral primary osteoarthritis, unspecified knee is an ICD-10-CM indexed diagnosis (M17.10) within Osteoarthritis, Gout & Joint Pain.
- 2 Real-world patient consensus: Mapped to Osteoarthritis, Gout & Joint Pain under ICD-10-CM M17.10 for Unilateral primary osteoarthritis, unspecified knee clinical workups.
- 3 Typical cash cost range: Clinicians assessing Unilateral primary osteoarthritis, unspecified knee focus on articular hyaline cartilage in Unilateral primary osteoarthritis, unspecified knee (M17.10: proteoglycan degradation) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Unilateral primary osteoarthritis, unspecified knee: Serum Uric Acid in Unilateral primary osteoarthritis, unspecified knee (M17.10: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M17.10)) and hs-CRP & Erythrocyte in Unilateral primary osteoarthritis, unspecified knee (M17.10: Sedimentation Rate).
Ask our AI Specialists anything about Unilateral primary osteoarthritis, unspecified knee
What Is Unilateral primary osteoarthritis, unspecified knee?
Unilateral primary osteoarthritis, unspecified knee is an ICD-10-CM indexed diagnosis (M17.10) within Osteoarthritis, Gout & Joint Pain. Clinical evaluation centers on synovial fluid crystal/cell in Unilateral primary osteoarthritis, unspecified knee (M17.10: analysis when effused) alongside serial Serum Uric Acid in Unilateral primary osteoarthritis, unspecified knee (M17.10: (Gout Target)) tracking (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M17.10)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Unilateral primary osteoarthritis, unspecified knee (ICD-10 M17.10) is driven by articular hyaline cartilage in Unilateral primary osteoarthritis, unspecified knee (M17.10: proteoglycan degradation); specialists in Osteoarthritis, Gout & Joint Pain monitor hs-CRP & Erythrocyte in Unilateral primary osteoarthritis, unspecified knee (M17.10: Sedimentation Rate) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Unilateral primary osteoarthritis, unspecified knee (M17.10): sudden, intensely painful, in Unilateral primary osteoarthritis, unspecified knee (M17.10: red swollen big-toe)
- • Secondary Unilateral primary osteoarthritis, unspecified knee clinical sign: localized tendon or in Unilateral primary osteoarthritis, unspecified knee (M17.10: bursa tenderness limiting)
- • Symptom flares in Unilateral primary osteoarthritis, unspecified knee correlating with Serum Uric Acid in Unilateral primary osteoarthritis, unspecified knee (M17.10: (Gout Target)) deviation outside < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M17.10)
- • Functional arthritis & joints impact requiring synovial fluid crystal/cell in Unilateral primary osteoarthritis, unspecified knee (M17.10: analysis when effused) evaluation (M17.10)
Unilateral primary osteoarthritis, unspecified knee Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M17.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Uric Acid in Unilateral primary osteoarthritis, unspecified knee (M17.10: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M17.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Unilateral primary osteoarthritis, unspecified knee (M17.10: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M17.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Unilateral primary osteoarthritis, unspecified knee M17.10] | Preserved joint-space width (M17.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Unilateral primary osteoarthritis, unspecified knee
Treatment selection for Unilateral primary osteoarthritis, unspecified knee depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Unilateral primary osteoarthritis, unspecified knee)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal In biologic-naive PsA patients, guselkumab provided sustained improvements across diverse manifestations and maintained a favorable risk-benefit profile through week 52. Arthritis & rheumatology (Hoboken, N.J.) • 2021-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33043600 ↗ |
| Can This Approach Help? Inside the Latest Research on Laryngeal Reinnervation vs Type I Thyroplasty in Unilateral Vocal Fold Paralysis The results from this study have provided us with the assurance that conducting an adequately powered randomized controlled clinical trial of laryngeal reinnervation versus type I thyroplasty for adults with UVFP in the UK is... The Laryngoscope • 2025-09-15 • Phase III Randomized Trial | N = 12 | 82/100 | PMID 40323143 ↗ |
| Can This Approach Help? Inside the Latest Research on Upadacitinib as single-drug treatment in patients with autoimmune joint pain No new safety risks were identified with long-term UPA treatment. RMD open • 2025-05-11 • Phase III Randomized Trial | N = 93 | 82/100 | PMID 40350200 ↗ |
| Can This Approach Help? Inside the Latest Research on VoiceS: voice quality after transoral CO 2 laser surgery versus single vocal cord Registered on 15 August 2019. Trials • 2022-10-27 • Phase III Randomized Trial | N = 34 | 82/100 | PMID 36303192 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber The treatment effect of lenadogene nolparvovec on BCVA and vision-related quality of life observed 96 weeks (2 years) after treatment in RESCUE and REVERSE was sustained at 3 years in RESTORE, with a maximum follow-up of 52. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society • 2021-09-01 • Phase III Randomized Trial | N = 76 | 82/100 | PMID 34415265 ↗ |
Unilateral primary osteoarthritis, unspecified knee Patient Community & “People Like Me” Threads
Filter Unilateral primary osteoarthritis, unspecified knee community threads and patient logs by age, biological sex, dosage, and treatment duration.